Corrigendum to: "TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study" [Eur Psychiatr 2008;23:390-5] (DOI:10.1016/j.eurpsy.2008.04.004);TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: An open label study

European Psychiatry

Volumn 23, Issue 6, 2008, Pages 390-395

  Pae, Chi Un ^a,b   Drago, Antonio ^c   Kim, Jung Jin ^a   Patkar, Ashwin A ^b   Jun, Tae Youn ^a   Lee, Chul ^a   Mandelli, Laura ^c   De Ronchi, Diana ^c   Paik, In Ho ^a   Serretti, Alessandro ^c  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Association; Gene; Schizophrenia; Trace amine associated receptor 6

Indexed keywords

NEUROPEPTIDE RECEPTOR; TRACE AMINE ASSOCIATED RECEPTOR 6; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOSITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; STRUCTURED INTERVIEW;

EID: 51249099165     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.10.001     Document Type: Erratum

References (34)

1. Abou Jamra R., Sircar I., Becker T., Freudenberg-Hua Y., Ohlraun S., Freudenberg J., et al. A family-based and case-control association study of trace amine receptor genes on chromosome 6q23 in bipolar affective disorder. Mol Psychiatry 7 (2005) 618-620
2. Amann D., Avidan N., Kanyas K., Kohn Y., Hamdan A., Ben-Asher E., et al. The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23. Mol Psychiatry 2 (2006) 119-121
3. Bailer U., Leisch F., Meszaros K., Lenzinger E., Willinger U., Strobl R., et al. Genome scan for susceptibility loci for schizophrenia. Neuropsychobiology 4 (2000) 175-182
4. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 16 (2001) 8966-8971
5. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 6 (2001) 1181-1188
6. Burchett S.A., and Hicks T.P. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol 5-6 (2006) 223-246
7. Cao Q., Martinez M., Zhang J., Sanders A.R., Badner J.A., Cravchik A., et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1 (1997) 1-8
8. Cavalli Sforza L. The history and geography of human genes (1994), Princeton University Press, Princeton
9. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 1 (2006) 9-16
10. Davis B., and Boulton A. The trace amines and their acidic metabolites in depression - an overview. Prog Neuropsychopharmacol Biol Psychiatry 1 (1994) 17-45
11. Duan J., Martinez M., Sanders A.R., Hou C., Saitou N., Kitano T., et al. Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. Am J Hum Genet 4 (2004) 624-638
12. *Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2 (2007) 175-191
13. Guy W. Assessment manual for psychopharmacology - revised (1976), DHEW Publ, Rockville p. 218-22
14. Hofer A.M., and Lefkimmiatis K. Extracellular calcium and cAMP: second messengers as "third messengers"?. Physiology (Bethesda) (2007) 320-327
15. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., et al. No association of haplotype-tagging SNPs in TRAR4 with schizophrenia in Japanese patients. Schizophr Res 2-3 (2005) 127-130
16. Jacob M.S., and Presti D.E. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med Hypotheses 5 (2005) 930-937
17. Kamenetsky M., Middelhaufe S., Bank E.M., Levin L.R., Buck J., and Steegborn C. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J Mol Biol 4 (2006) 623-639
18. Kaufmann C.A., Suarez B., Malaspina D., Pepple J., Svrakic D., Markel P.D., et al. NIMH Genetics Initiative Millennium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 4 (1998) 282-289
19. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 2 (1987) 261-276
20. Kay S.R., and Opler L.A. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev 2 (1987) 79-103
21. Lerer B., Segman R.H., Hamdan A., Kanyas K., Karni O., Kohn Y., et al. Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24. Mol Psychiatry 5 (2003) 488-498
22. Levinson D.F., Holmans P., Straub R.E., Owen M.J., Wildenauer D.B., Gejman P.V., et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. Am J Hum Genet 3 (2000) 652-663
23. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 1 (2003) 34-48
24. Lindemann L., Ebeling M., Kratochwil N.A., Bunzow J.R., Grandy D.K., and Hoener M.C. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 3 (2005) 372-385
25. Lindholm E., Ekholm B., Shaw S., Jalonen P., Johansson G., Pettersson U., et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet 1 (2001) 96-105
26. Maier W., Hofgen B., Zobel A., and Rietschel M. Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes?. Eur Arch Psychiatry Clin Neurosci 3 (2005) 159-166
27. Martinez M., Goldin L.R., Cao Q., Zhang J., Sanders A.R., Nancarrow D.J., et al. Follow-up study on a susceptibility locus for schizophrenia on chromosome 6q. Am J Med Genet 4 (1999) 337-343
28. Pae C.U., Yu H.S., Amann D., Kim J.J., Lee C.U., Lee S.J., et al. Association of the trace amine associated receptor 6 (TAAR6) gene with schizophrenia and bipolar disorder in a Korean case control sample. J Psychiatr Res 1 (2008) 35-40
29. Potkin S.G., Karoum F., Chuang L.W., Cannon-Spoor H.E., Phillips I., and Wyatt R.J. Phenylethylamine in paranoid chronic schizophrenia. Science 4417 (1979) 470-471
30. Sandler M., Ruthven C.R., Goodwin B.L., and Coppen A. Decreased cerebrospinal fluid concentration of free phenylacetic acid in depressive illness. Clin Chim Acta 1 (1979) 169-171
31. Vladimirov V., Thiselton D.L., Kuo P.H., McClay J., Fanous A., Wormley B., et al. A region of 35 kb containing the trace amine associated receptor 6 (TAAR6) gene is associated with schizophrenia in the Irish study of high-density schizophrenia families. Mol Psychiatry 9 (2007) 842-853
32. Walss-Bass C., Escamilla M.A., Raventos H., Montero A.P., Armas R., Dassori A., et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am J Med Genet B Neuropsychiatr Genet 1 (2005) 54-60
33. Wolinsky T.D., Swanson C.J., Smith K.E., Zhong H., Borowsky B., Seeman P., et al. The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 7 (2007) 628-639
34. Zucchi R., Chiellini G., Scanlan T.S., and Grandy D.K. Trace amine-associated receptors and their ligands. Br J Pharmacol 8 (2006) 967-978